Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Diphenhydramine | Aleryl | |||
Flotetuzumab | MGD006|S80880 | Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488). | ||
Ibuprofen | Act-3 | Ibuprophen | ||
Ranitidine | Alquen | Ranitidine HCL |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |